2076975 2077203
최종편집 2024-06-18 17:24 (화)
NovartisㆍJanssen received the most patent-approval by the MFDS in February  
상태바
NovartisㆍJanssen received the most patent-approval by the MFDS in February  
  • Hyeokgi Lee, Newsmp
  • 승인 2022.03.10 11:54
  • 댓글 0
이 기사를 공유합니다

Approved 6 cases each… Teva-Handok 4 cases, followed by Hana PharmㆍOno Pharmaceutical KoreaㆍPfizer Pharmaceutical Korea 3 cases

The Korean Ministry of Food and Drug Safety (MFDS) approved a total of 36 patents in February.

According to the MFDS’ information platform (https://nedrug.mfds.go.kr/), Tabrecta-related (Novartis) patents accounted for the most with six, followed by Invega Sustenna Inj. (Janssen Korea) with five among the 36 patents.

A total of four cases were registered for Ajovy (Teva-Handok), two each for Auto Injector Inj. and Prefilled Syringe Inj., while three cases were listed for Byfavo Inj. (Hana Pharm), Velexbru Tab. (Ono Pharmaceutical Korea), and Cibinqo Tab. (Pfizer Pharmaceutical Korea).

Moreover, AKLIEF Cream (Galderma Korea), Tepmeko Tab. (Merck), Skilarence Enteric Coated Tab. (Kolon Pharmaceutical), Tagrisso Tab. (AstraZeneca Korea), and Abilify Tab. (Korea Otsuka Pharmaceuticals) secured two cases each, and Covid-19 Vaccine Janssen Inj. (Janssen Korea) and Tecentriq Inj. (Roche Korea) one case.

By company, Novartis and Janssen were approved the most by six cases. Teva-Handok had four cases, and Hana Pharm, Ono Pharmaceutical Korea, and Pfizer Pharmaceutical Korea three cases.

Galderma Korea, Merck, Kolon Pharmaceutical, AstraZeneca Korea, and Korea Otsuka Pharmaceuticals followed with two cases, while Roche listed one. 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.